WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (“Eagle” or “the Company”) (Nasdaq:EGRX) today announced its financial results for the three- and twelve-month periods ended December 31, 2015. Highlights of and subsequent to the fourth quarter of 2015 include:
Business Highlights:
• Received approval from the U.S. Food and Drug Administration (“FDA”) of BENDEKA™, triggering a $15 million milestone payment from Teva Pharmaceutical Industries Ltd. The Company will receive a 20% royalty on net sales of BENDEKA, which became commercially available as of January 28, 2016, as well as a potential incremental step-up royalty upon the achievement of a future milestone;
